Bioxytran (QTCQB:BIXT) announced that it has signed a non-disclosure agreement (NDA) with the board of regents of the University System of Georgia, University of Georgia (UGA), to collaborate on evaluating its galectin antagonist, ProLectin-M, as a potential treatment for chickens infected with avian influenza (bird flu).
The company states that renowned virology and poultry medicine expert, Dr. Daniel Perez, CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine, at UGA, will lead research.
According to Bioxytran, ProLectin-M is a novel drug candidate designed to combat viral infections by targeting galectins—proteins implicated in viral replication, inflammation, and fibrosis. In vitro studies have demonstrated its effectiveness against viruses similar to bird flu.
